Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGRADIS: Lugol's Solution in Graves' Disease
NCT03980132Phase 4Completed
- Start
- Nov 2019
- Primary completion
- Nov 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of Lugol's solution in Graves' disease (2 arms). Primary endpoint: Postoperative complications at 30 days. Started Nov 2019; status: completed.
02
Drugs
Lugol's solution
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT03980132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03980132.